Targeted therapies in melanoma.

Article Details

Citation

Copy to clipboard

Moschos SJ, Pinnamaneni R

Targeted therapies in melanoma.

Surg Oncol Clin N Am. 2015 Apr;24(2):347-58. doi: 10.1016/j.soc.2014.12.011. Epub 2015 Jan 24.

PubMed ID

25769717 [ View in PubMed

]

Abstract

Advances in the biology of melanoma have provided insights about chemoresistance and its genetic heterogeneity in parallel with advances in drug design, culminating in recent major treatment breakthroughs. Although clinical benefit of targeted therapies has been unquestionable, future advances are only possible if we understand the interplay between genetic aberrations and role of other crucial nongenetic changes yet to be identified by such projects as the Cancer Genome Atlas Project in Melanoma. Combination therapies, either among small molecule inhibitors themselves and/or with immunotherapies, may be the optimal strategy to prevent development of drug resistance inherently linked with such targeted therapies.

DrugBank Data that Cites this Article

Drugs

Encorafenib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Encorafenib	Serine/threonine-protein kinase B-raf	Protein	Humans	Yes	Inhibitor	Details